Detalhe da pesquisa
1.
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Am J Respir Crit Care Med
; 205(5): 529-539, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784492
2.
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Am J Respir Crit Care Med
; 190(2): 175-84, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24927234
3.
Highly effective cystic fibrosis clinical research teams: critical success factors.
J Gen Intern Med
; 29 Suppl 3: S714-23, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25029977
4.
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
J Clin Invest
; 133(10)2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36976651
5.
A pipeline of therapies for cystic fibrosis.
Semin Respir Crit Care Med
; 30(5): 611-26, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19760548
6.
How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?
Pediatr Pulmonol
; 39(6): 504-6, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15830388
7.
In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.
J Pediatric Infect Dis Soc
; 4(2): 151-4, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26407415
8.
Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.
J Clin Microbiol
; 40(1): 26-30, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11773088